New visions in the pharmacology of anticonvulsion

European Journal of Pharmacology
W Löscher

Abstract

Seizures are resistant to treatment with currently available anticonvulsant drugs in about 1 out of 3 patients with epilepsy. Thus, there is a need for new, more effective anticonvulsant drugs for intractable epilepsy. Furthermore, because of the inadequacy of the currently available anticonvulsant armamentarium with respect to safety, newly developed drugs should be less toxic than existing drugs. Previous and current strategies for development of novel anticonvulsants with improved efficacy or safety are critically discussed in this review. 'Old drugs' (or 'first generation' drugs), which were developed and introduced between 1910 and 1970, are compared with new anticonvulsants both in terms of clinical efficacy and safety and in terms of mechanisms of action. The new drugs are referred to as 'second generation' drugs, i.e. anticonvulsants which have been introduced into clinical practice in recent years, or 'third generation' drugs, i.e. compounds in the pipeline of development. In spite of some 30 years of 'modern' neuroscientific epilepsy research, most novel, clinically effective second generation anticonvulsants have been found by screening (i.e. serendipity) or structural variation of known drugs and not by rational str...Continue Reading

References

Feb 1, 1991·Trends in Pharmacological Sciences·W Löscher, D Hönack
May 1, 1990·Trends in Pharmacological Sciences·B Fredholm, A Abbott
Aug 1, 1990·Trends in Pharmacological Sciences·R DingledineJ O McNamara
Nov 22, 1990·The New England Journal of Medicine·M L Scheuer, T A Pedley
May 1, 1990·Naunyn-Schmiedeberg's Archives of Pharmacology·W Löscher, D Hönack
Oct 30, 1989·Brain Research·W Löscher
Jan 1, 1989·Epilepsia·R L Macdonald
Feb 1, 1986·Behavioural Brain Research·A P LecceseJ E Moreton
Dec 1, 1980·Epilepsia·W Löscher, D Schmidt
Dec 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D Schmidt, G Krämer
Jan 9, 1993·Lancet·W LöscherH Stefan
Jan 1, 1996·Annals of Neurology·O A PetroffR H Mattson
May 1, 1996·Nature Medicine·K M Allen, C Walsh
May 1, 1996·Trends in Pharmacological Sciences·E Costa, A Guidotti
Jan 1, 1995·Epilepsia·R L Macdonald, K M Kelly
Jan 1, 1995·Pharmacology & Therapeutics·B Rogvi-Hansen, L Gram
Sep 1, 1996·Epilepsy Research·L ThomasH Ring
Aug 1, 1996·Acta Neurologica Scandinavica·M Dam
Nov 1, 1996·British Journal of Clinical Pharmacology·E Perucca
Apr 1, 1997·Epilepsia·R W Olsen, M Avoli
Nov 19, 1997·Progress in Neurobiology·W Löscher
Jan 27, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Vladimir V Kalinin
Feb 1, 1997·CNS Drugs·W Löscher

❮ Previous
Next ❯

Citations

Dec 25, 2012·Archives of Pharmacal Research·Samir BotrosYara El-Dash
Jan 18, 2013·Archives of Pharmacal Research·Mohd AmirMohd Zaheen Hassan
Jun 15, 2005·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·Alexandra Olimpio Siqueira CunhaWagner Ferreira dos Santos
Jun 12, 2013·Neurochemistry International·Kamila Soares LopesAlice Maria Costa Martins
Jan 3, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Roger J PorterChris Rundfeldt
Jul 6, 2000·European Journal of Pharmacology·M SwiaderS J Czuczwar
Nov 17, 2001·European Journal of Pharmacology·R M KamińskiG Van Luijtelaar
Jul 13, 2001·Pharmacology & Therapeutics·P KwanM J Brodie
Apr 21, 1999·Brain Research. Brain Research Reviews·A K Mehta, M K Ticku
Mar 7, 2002·Trends in Pharmacological Sciences·Wolfgang Löscher
Aug 2, 2002·Epilepsy Research·Wolfgang Löscher, Dieter Schmidt
Aug 2, 2002·Epilepsy Research·J P LeiteE A Cavalheiro
Apr 4, 2002·Neuroreport·Bálint LasztócziJulianna Kardos
Jun 11, 2005·Epilepsia·Dieter Schmidt, Wolfgang Löscher
Jul 6, 2005·Biological & Pharmaceutical Bulletin·Li-Jing CuiZhe-Shan Quan
Jul 24, 2001·Drugs·N R TemkinG D Anderson
Jul 31, 2001·CNS Drugs·S J Czuczwar, P N Patsalos
Nov 19, 2003·Psychopharmacology Bulletin·Michael J Owens, Charles B Nemeroff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.